DSDienifer Hermann Sirena

Dienifer Hermann Sirena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dienifer Hermann Sirena has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low‐Risk Basal Cell Carcinoma

    by Rodrigo Pérez Pereira, Dienifer Hermann Sirena, Sérgio Jobim de Azevedo, Monique Maria Franco da Silva, Mariani Magnus da Luz Andrade, Charles Francisco Ferreira, Tiago Elias Heinen, Renato Marchiori Bakos

    Recently, new treatment strategies have been developed for advanced or metastatic basal cell carcinoma (BCC), including Hedgehog pathway inhibitors. Itraconazole has demonstrated clinical activity in such cases by blocking the smoothened (SMO) receptor. Such a strategy could be used in early disease. The objective of this Phase II study was to evaluate the clinical and molecular efficacy of Itraconazole in low‐risk BCC patients who were primarily candidates for surgical excision. Lesions were assessed according to RECIST 1.1 criteria, with target lesions being at least 10 mm in size after confirmatory biopsy. Patients received itraconazole tablets 200 mg twice daily for 60 days before resection. The median tumour diameter before treatment was 14 mm (IQR 11–16 mm), and after treatment, 13 mm (IQR 11–15 mm), and this reduction in tumour size was statistically significant ( p < 0.0001). Coupled with the decrease in tumour size, a decrease in the expression of CD105, an endothelial marker ( p < 0.0001), was observed. In conclusion, neoadjuvant itraconazole for 2 months was able to reduce the diameter of low‐risk BCC, and the effect was associated with a decrease in tumour angiogenesis and a favourable safety profile.


  • Open Access

    Guarana (Paullinia cupana) as a potential tool for mesenchymal stromal cells priming in regenerative medicine

    by D.H. Sirena, A.B. Araújo, A.B.T da Silveira, M.A. Serafini, M.M.F. da Silva, A.K. Silveira, E. Filippi-Chiela, J.C.F. Moreira, A.H. Paz

    Mesenchymal stromal cells (MSCs) have therapeutic potential due to their abilities of differentiation, immunomodulation, and migration to injured tissues, potentiating such effects when cells are activated. Guarana (Paullinia cupana) is a tropical plant species found in South America that is known for its antioxidant, stimulant, and cicatricial effects. The guarana extract is composed of many substances and caffeine is the main component. The objective was to evaluate the effects of guarana and caffeine on MSCs. After the initial characterization, MSCs were treated with Paullinia cupana (10, 100, and 1000 μg/mL) or caffeine (0.4, 4, and 40 μg/mL) for 24 h. MSCs treatment with 1000 μg/mL guarana increased cell polarity, viability, cell migration to chemoattractant, antioxidant potential, and liberation of extracellular vesicles (EVs), while it reduced the levels of autophagy. MSCs treated with 100 and 1000 μg/mL guarana or 40 μg/mL caffeine showed a decrease of cell proliferation. No treatment affected the cellular area and cell cycle of MSCs. The study shows in vitro evidence that guarana could be a promising alternative for activating MSCs to promote better cellular products for future clinical therapies.